The largest database of trusted experimental protocols

S plus version 8

Manufactured by TIBCO Software
Sourced in United States

S-Plus Version 8.2 is a statistical software package developed by TIBCO Software. It provides a comprehensive set of tools for data analysis, modeling, and visualization. The core function of S-Plus is to enable users to perform a wide range of statistical computations and generate graphical representations of data.

Automatically generated - may contain errors

9 protocols using s plus version 8

1

Phenotypic Characterization of Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
All data were analyzed using descriptive statistics. Continuous variables were summarized using measures of central tendency and variability. Categorical variables were summarized using absolute and relative frequencies. Differences between groups were assessed using a generalized linear mixed model for binary data using the logit-link with enrichment system as fixed factor and donor as random factor. For analysis of the cell-and nucleus diameters of the phenotypic characterization with DEPArray Nxt image analysis a linear mixed model was used. Corrections for simultaneous hypothesis testing were performed according to Sidak. Residual analysis by means of normal quantile plots showed that a log-transformation had to be applied to the data. All analyses were performed in S-PLUS version 8 (TIBCO Software), with a two-sided P-value <0.05 considered as statistically significant.
+ Open protocol
+ Expand
2

Metabolic Profiling in Fasting and Glucose-Loaded States

Check if the same lab product or an alternative is used in the 5 most similar protocols
Data processing and analysis were performed using S-PLUS version 8 (TIBCO Software, Inc., Palo Alto, CA, USA), with a two-tailed P value of < 0.05 considered statistically significant. For the analysis of patient characteristics, Fisher’s exact tests and Mann–Whitney U tests were used to investigate differences between fasting and glucose-loaded groups. Spearman’s rank correlation coefficient was used to examine correlations between two parameters selected from the liver histology score (lobular inflammation, hepatocyte ballooning, steatosis grade, fibrosis stage), physical variables (age, sex, body mass index), results of blood tests, and expression levels of IRS1, IRS2, β-catenin, and GCK. To investigate relationships between blood glucose levels at 120 min or the Matsuda Index of insulin sensitivity and each parameter, we used the Spearman’s rank correlation coefficient for univariate analysis and a linear regression model for multivariate analysis. For this, we explored model selection using the Akaike information criterion. For the analysis of T2DM risk factors, we used univariate and multivariate Cox hazard regression analysis.
+ Open protocol
+ Expand
3

Lung Cancer Screening Decision Aid

Check if the same lab product or an alternative is used in the 5 most similar protocols
After completing the baseline assessment, clients within each state quit line were randomized to receive the PDA or standard educational material (EDU) using S-plus, version 8.04 (TIBCO Software Inc) statistical software to generate a randomization schedule with various block sizes. Participants were not blinded to intervention allocation. Study interviewers were blinded to participant allocation at the 3- and 6-month assessments, but not the 1-week follow-up because questions about the PDA were asked of participants in this group. Participants received the PDA intervention materials via mail in DVD format 1 week before the first follow-up assessment; they were also offered a weblink to the video (2 participants requested a weblink). Participants randomized to EDU were mailed a 2-page brochure about lung cancer screening. When needed, research coordinators assisted participants in finding a location where they could view the PDA such as a public library. Participants in both groups were encouraged to discuss screening with a health care clinician, but they were not given specific guidance on locating a screening facility.
+ Open protocol
+ Expand
4

Statistical Methods for Preclinical Myeloma

Check if the same lab product or an alternative is used in the 5 most similar protocols
For in vitro experiments, statistical analyses and figure generations were performed using Excel (Microsoft Corporation, Redmond, WA, USA) and GraphPad Prism 6 (GraphPad Software Inc, La Jolla, CA, USA). Error bars were represented as the standard error of the mean (SEM), and significance of drug effects was further evaluated using a one-tailed Student’s paired t-test. The Kaplan-Meier method was used to estimate the distribution of overall survival (OS), and log-rank testing was performed to evaluate the difference in survival between groups, with OS defined as the time from tail-vein injection of myeloma cells to the time of death or of euthanasia. SAS version 9.2 (SAS Institute, Inc., Cary, NC, USA) and S-Plus version 8.04 (TIBCO Software, Inc., Palo Alto, CA, USA) were used to carry out the computations for in vivo experiments.
+ Open protocol
+ Expand
5

Evaluating Dysphagia Severity Grading

Check if the same lab product or an alternative is used in the 5 most similar protocols
Weighted Kappa was used to assess intra- and inter-rater reliability. Criterion validity against Oropharyngeal Swallow Efficiency (OPSE),8 (link) Modified Barium Swallow Impairment Profile (MBSImP™©),9 (link) M.D. Anderson Dysphagia Inventory (MDADI),10 (link) and Performance Status Scale for Head and Neck Cancer Patients (PSS-HN)11 (link) was assessed with one-way ANOVA and post hoc pairwise comparisons between DIGEST grades using the CONTRAST statement in PROC GENMOD procedure with a Wald chi-square statistic option. Weighted Kappa was used to assess agreement between CTCAE grades assigned by the expert panel and a lab rater’s post hoc analysis of DIGEST scores. SAS version 9.2 (SAS Institute Inc., Cary, NC) and S-Plus version 8.04 (TIBCO Software Inc., September 3, 2008) were used to carry out the computations for all analyses.
+ Open protocol
+ Expand
6

Analyzing Tumor Growth in Xenograft Models

Check if the same lab product or an alternative is used in the 5 most similar protocols
The t-test or ANOVA, or their corresponding nonparametric methods (Wilcoxon rank-sum test or Kruskal-Wallis test), were used to detect differences for continuous variables between groups (20 ). Generalized linear regression models (21 (link)) were used to study the tumor growth over time in the xenograft model. Autoregressive (20 ) covariance structure was used to account for inter-mouse variability and the longitudinal nature of the data. An interaction between treatment and time is assessed to test the heterogeneity of slopes, i.e., the tumor growth rate. A two-sample t-test was used to compare the differences of tumor volume between the two groups at each time point. The transformation of logarithm to the base 2 of the tumor volume was used in the analyses to satisfy the normality assumption of the models, and Bonferroni multiplicity adjustment was applied for multiple comparisons. SAS version 9.2 (SAS; Cary, NC), R 2.80 and S-Plus version 8.04 (TIBCO Software, Inc.; Palo Alto, CA) were used to carry out the computations for all analyses.
+ Open protocol
+ Expand
7

Analyzing Costs of Healthcare Utilization

Check if the same lab product or an alternative is used in the 5 most similar protocols
Descriptive statistics were calculated. For comparing categorical and continuous variables, P-values were computed from Chi-squared tests and t-tests, respectively. Multivariate analyses were conducted on the cost of treatment, transportation/food/accommodations, medicine/supplies, unofficial gifts (to doctors and nurses), lost income (due to illness), total cost, and OOP cost. Total cost was defined as the sum of the cost of treatment, transportation/food/accommodations, medicine/supplies, unofficial gifts, and lost income. OOP cost was defined as the total cost minus insurance payment. In the analysis of total and OOP costs, a linear regression was conducted. The analyses were carried out using S-Plus Version 8.2 (TIBCO Software Inc.).
+ Open protocol
+ Expand
8

Racial Disparities in Cystic Fibrosis Prevalence

Check if the same lab product or an alternative is used in the 5 most similar protocols
All data were categorized according to the self-reported racial background of the birth mother: NHW, NHB, Hispanic, or Other. The “Other” category captured participants who did not identify as NHW, NHB, or Hispanic. The incidence of CF births was then adjusted for racial background. Estimates of period prevalence were calculated as the number of events for a racial group divided by the size of the Wisconsin population self-reporting as that race or by the number of total births in Wisconsin (E-Table 1), then multiplied by 10,000. In general, missing or incomplete data points were excluded from analysis. However, we did examine prevalence trends for cases lacking self-reported race data.
Spearman’s nonparametric rank correlation coefficient (ρ) was calculated for correlations of continuous variables and Fisher’s exact test was performed to test categorical variables. Trends over time were fitted with a cubic spline. Statistical analyses were carried out with SPlus version 8.2 (TIBCO Software, Palo Alto, CA) and SPSS version 21 (IBM Software, Chicago, IL). Unadjusted P-values <0.05 were reported as significant; actual values are also reported.
+ Open protocol
+ Expand
9

Pharmacokinetic and Pharmacodynamic Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Pharmacodynamic endpoints and changes from baseline were summarized using descriptive statistics by time point or collection interval and tolvaptan dose using SAS version 9.1 (Trial 202) or version 9.4 (Trial 203) (SAS Institute, Cary, NC). PK descriptive statistics were determined using S-Plus, version 8.2 (TIBCO Software, Inc., Boston, MA). Slopes and 95% confidence intervals (CIs) of plots of individual subject log dose versus Log Cmax or Log AUC were determined in Sigma Plot, version 12.5 (Systat Software, Inc., San Jose, CA) as were correlations between maximal increases in serum sodium, fluid balance, and urine volume.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!